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Abstract
Background: Non-contact cranial cruciate ligament rupture (CrCLR) is an important cause of lameness in client-owned dogs
and typically occurs without obvious injury. There is a high incidence of bilateral rupture at presentation or subsequent
contralateral rupture in affected dogs. Although stifle synovitis increases risk of contralateral CrCLR, relatively little is known
about risk factors for subsequent contralateral rupture, or whether therapeutic intervention may modify this risk.
Methodology/Principal Findings: We conducted a longitudinal study examining survival of the contralateral CrCL in client-
owned dogs with unilateral CrCLR in a large baseline control population (n=380), and a group of dogs that received
disease-modifying therapy with arthroscopic lavage, intra-articular hyaluronic acid and oral doxycycline (n=16), and were
followed for one year. Follow-up in treated dogs included analysis of mobility, radiographic evaluation of stifle effusion and
arthritis, and quantification of biomarkers of synovial inflammation. We found that median survival of the contralateral CrCL
was 947 days. Increasing tibial plateau angle decreased contralateral ligament survival, whereas increasing age at diagnosis
increased survival. Contralateral ligament survival was reduced in neutered dogs. Our disease-modifying therapy did not
significantly influence contralateral ligament survival. Correlative analysis of clinical and biomarker variables with
development of subsequent contralateral rupture revealed few significant results. However, increased expression of T
lymphocyte-associated genes in the index unstable stifle at diagnosis was significantly related to development of
subsequent non-contact contralateral CrCLR.
Conclusion: Subsequent contralateral CrCLR is common in client-owned dogs, with a median ligament survival time of 947
days. In this naturally occurring model of non-contact cruciate ligament rupture, cranial tibial translation is preceded by
development of synovial inflammation. However, treatment with arthroscopic lavage, intra-articular hyaluronic acid and oral
doxycycline does not significantly influence contralateral CrCL survival.
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Introduction
Non-contact cranial cruciate ligament rupture (CrCLR) is an
important cause of lameness in the dog that incurs substantial
annual health-care costs [1]. It is now widely recognized that mid-
substance rupture of the CrCL often occurs during normal
activity, with a high incidence of bilateral rupture at the time of
initial clinical presentation in the range of 11–17% [2–4]. The
CrCL in dogs is anatomically equivalent to the anterior cruciate
ligament (ACL) in human beings, and the dog is a widely used
model for research into ACL biology and repair.
A number of studies have examined the incidence of subsequent
contralateral CrCLR in dogs diagnosed with unilateral non-contact
CrCLR at initial presentation. Analysis of this risk has usually been
reported as an incidence after surgery (percentage of patients within the
cohort). This risk is in the range of 22–54% at 6 to 17 months of
diagnosis [2,3,5–7]. One of the limitations of this approach to data
analysis is that it yields little information on the pattern of subsequent
contralateral rupture. It has been our clinical impression that individual
dogs appear at particularly high risk of subsequent contralateral
CrCLR, whereas other dogs are protected from the trait. Estimation of
ligament survival over time would provide more detailed information
on the pattern of subsequent contralateral CrCLR.
In the past, development of stifle arthritis was thought to occur
secondary to development of joint instability associated with
progressive CrCLR. However, this perspective may not be correct,
since development of stifle synovitis is an early event that can often
be found before fraying of the cruciate ligaments becomes
arthroscopically detectable in dogs with incipient disease [8].
Ligament damage typically involves both the CrCL and the caudal
cruciate ligament [9]. Development of stifle synovitis also increases
the risk of subsequent contralateral CrCLR in dogs [10].
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suggests that immune-mediated joint degeneration is a factor in
the non-contact CrCLR mechanism. The cruciate ligaments are
wrapped in synovium [11]; synovial vasculature has a blood-CrCL
barrier, analogous to the blood-brain barrier [12], suggesting that
inflammatory changes within synovium and synovial fluid have
profound effects on cruciate ligament tissue metabolism. It is also
known that chronic synovitis induces marked deterioration in
CrCL structural properties in a rabbit model [13]. Histologic
features of lymphoplasmacytic synovitis are present in stifle joints
of 51–67% affected dogs at the time of initial diagnosis [10,14]. In
affected dogs, inflammatory cell populations within stifle synovium
are usually mononuclear, and include T lymphocytes, B
lymphocytes, major histocompatibility complex (MHC) class II
+
dendritic cells, and activated macrophages, expressing tartrate-
resistant acid phosphatase (TRAP) [15–18]. TRAP
+ mononuclear
cells are not found in normal stifle synovium of dogs [17].
At the present time, there are two hypotheses regarding the
mechanism that leads to development of inflammatory stifle
arthritis and eventual CrCLR: (1) cruciate fiber rupture is a
consequence of a primary synovitis [8], and (2) intrinsic and
extrinsic factors induce fiber rupture, with subsequent induction of
synovitis by ligament matrix neoepitopes [19–21]. The immuno-
logic trigger for synovitis for the first hypothesis is not known,
although the presence of bacterial material within the stifle has
been associated with the condition [22–24].
If development of synovitis has a significant role in the
pathogenesis of progressive non-contact rupture of the cruciate
ligament complex, particularly the CrCL, then disease-modifying
medical therapy may block progressive stifle joint degeneration in
dogs with incipient disease, and lead to a reduction in the
incidence of non-contact cruciate rupture over time. In this regard,
evaluation of the status of the contralateral CrCL over time in
dogs with unilateral CrCLR would be one model that could be
used to address this question.
The first objective of the study was to conduct a survival analysis
of time to contralateral CrCLR in a large population of dogs with
unilateral CrCLR presented for surgical treatment, to determine
the pattern of subsequent contralateral CrCLR that is typically
found in affected dogs. We hypothesized that within a large
population of affected dogs, some dogs would appear protected
from the risk of subsequent contralateral rupture. A secondary
objective of this study was to determine whether treatment of a
group of dogs with a provisional disease-modifying therapy for
arthritis might ameliorate risk of subsequent contralateral rupture,
and whether a biomarker for subsequent contralateral rupture risk
could be identified.
Materials and Methods
Dogs
In order to determine the pattern of subsequent contralateral
CrCLR in affected dogs, we performed a survival analysis of three
populations of dogs from different regions of the USA; data from
two of these cohorts has been previously published with limited
analysis on contralateral CrCL survival [2,3]. Dogs with unilateral
CrCLR that were treated surgically were studied.
In Group 1, a cohort of 125 dogs [2] presented to the
Department of Surgery, VCA West Los Angeles Hospital, Los
Angeles, CA between 2000 and 2006 was studied. In Group 2,a
cohort of 84 Labrador retrievers [3] presented to the Animal
Medical Center, New York, NY and Dallas Veterinary Surgical
Center, Dallas, TX between 2000 and 2003 was studied. In Group
3, a cohort of 171 dogs was studied at the University of Wisconsin-
Madison, School of Veterinary Medicine, Veterinary Medical
Teaching Hospital, Madison, WI. Initially, the medical records of
all dogs (298 dogs) that received surgical treatment during the
period 2007–2009 were reviewed for inclusion in the survival
analysis. Of these records, 51 were excluded because of incomplete
data or were lost to follow-up, 16 were excluded because a disease-
modifying treatment with intra-articular hyaluronic acid and
doxycycline was provided (see below), and 60 were excluded
because the dog was found to have bilateral CrCLR on initial
examination. The remaining 171 records were included in the
study and examined in detail. In Group 4, a cohort of 16 dogs with
unilateral CrCLR rupture and clinical and radiographic evidence
of incipient non-contact cruciate rupture in the contralateral stifle
were studied. Dogs presented to the University of Wisconsin-
Madison, School of Veterinary Medicine, Veterinary Medical
Teaching Hospital, Madison, WI [8] were studied, after treatment
with a single intra-articular injection of hyaluronic acid (HA) and a
course of oral doxycycline. Doxycycline has been previously
reported to have disease-modifying effects on arthritic joints in
human beings and dogs [25–27]. All procedures at the University
of Wisconsin-Madison were conducted with the approval of the
Animal Care & Use Committee, School of Veterinary Medicine,
University of Wisconsin-Madison (V1070).
Medical records review
For inclusion in the analysis, CrCLR was confirmed during
surgical treatment, with clinical follow-up of a least one year for
censored cases. Breed, age, bodyweight, and gender were obtained
from the medical record. Pre-operative tibial plateau angle (TPA)
in the index stifle was also recorded [2,3] in all groups. If the dog
developed a subsequent contralateral CrCLR during the study
period, the time interval to contralateral CrCLR was recorded in
days as a complete case. For dogs that did not experience a
contralateral CrCLR, the time interval to clinical or telephone
follow-up was recorded, as a censored case.
Follow-up information was obtained from the medical record,
by telephone conversation with the owner, or telephone
conversation with the attending clinician, if surgery for subsequent
contralateral CrCLR had been performed at a different hospital,
as previously described [2,3]. In the Groups 2 and 3, a standard
questionnaire was used to obtain telephone follow-up, as
previously described [3].
Provisional disease-modifying therapy for synovitis/
arthritis
Initial clinical, radiographic, and arthroscopic findings in the
cohort of dogs in Group 4 have been previously reported [8].
Inclusion criteria for this cohort of dogs included 1) pelvic limb
lameness; 2) clinical and radiographic signs of synovial effusion
and arthritis in both stifles; 3) stifle instability in the index stifle; 4)
no clinically detectable instability in the contralateral stifle based
on palpation and stress radiographic examination [8]; 5) no history
of traumatic injury; and 6) no previous stifle surgery.
Age, weight, gender, and history were recorded. Bilateral
orthogonal stifle radiographs were made immediately before
surgery, at 10 weeks after surgery, and at long-term follow-up at
least 12 months after surgery. Radiographs were graded for the
following parameters: ‘‘overall disease severity’’ (0–3), ‘‘joint
effusion’’ (0–2), ‘‘osteophytosis’’ (0–3) and ‘‘intraarticular miner-
alization’’ (0–2) [28]. Radiographic grading was performed by a
single observer (PM). In addition during the initial visit and at
long-term follow-up, stress radiographs of the contralateral stifle
were made [8]. Dogs were positioned in lateral recumbency, with
the affected stifle resting on the x-ray table. The x-ray beam was
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tibial and femoral diaphysis. A standard lateral view was taken
with the joint in approximately 90–110 degrees of flexion (neutral
view). For the tibial compression view, the stifle was maintained as
the same angle of flexion, and manual stress was applied to the
metatarsals to flex the hock joint maximally (stress view). Cranial
tibial translation was then measured [8] by a single observer (ZS).
During surgical stabilization of the index stifle with tibial
plateau leveling osteotomy (TPLO), arthoscopic examination of
the unstable index and contralateral stable stifle joints was
performed [8]. Pain management was supervised by a board-
certified veterinary anesthesiologist. Dogs were premedicated,
anesthetized, and administered an epidural or regional nerve block
before surgery. No intra-articular anesthetic agents were used.
Immediately after surgery, 20 mg of HA (Hylartin V, Pfizer
Animal Health, New York, NY) was injected into each stifle and
doxycycline was given orally at 5 mg/kg b.i.d. for 10 weeks.
Clinical follow-up of HA/doxycycline-treated dogs
Follow-up visits were performed at 10 weeks and at least one
year, except for one dog that died shortly before one year after
surgery. At the long-term recheck each owner was asked to
complete a specific outcome measure questionnaire based on the
‘‘Liverpool Osteoarthritis in Dogs’’ (LOAD) questionnaire [29]. In
completing the LOAD questionnaire, owners were asked to score
the function of the dog in the period immediately before surgery
and then again in the period immediately before the long-term
follow-up visit. The total possible score ranged from 0–52, with 0
being normal.
Force-plate analysis-of-gait was also performed at long-term
follow-up. Peak vertical force (Fz) and vertical impulse (VI)
normalized to body weight were obtained [30]. A biomechanical
platform that measures 3-dimensional forces and impulses (OR6-
6-1000 Biomechanics Platform with SGA6-4 Signal Conditioner/
Amplifier, Advanced Mechanical Technologies Inc., Newton, MA)
was used. The force plate was connected to a commercially
available satellite data acquisition system (Sharon Software Inc.,
Dewitt, MI). The velocity of each trial was measured. At least 5
successful trials were obtained from each dog, other than one dog
in which only 4 trials were obtained. A successful trial was defined
by a thoracic limb hitting the plate followed by the ipsilateral
pelvic limb within the predetermined velocity range of 1.1 to
1.8 m/s and an acceleration range of 20.5 m/s
2 to +0.5 m/s
2.
Collection of peripheral blood and joint tissue specimens
from HA/doxycycline-treated dogs
A peripheral blood sample was collected into a vacutainer tube
(BD Vacutainer
TM CPT
TM, Becton Dickinson, Franklin Lakes,
NJ) during each visit. Peripheral blood mononuclear cells (PBMC)
were subsequently isolated by centrifugation. During surgery,
synovial membrane and synovial fluid specimens were collected
bilaterally. Synovium was collected from the lateral suprapatellar
region of the stifle at the site of the egress portal using aseptic
technique [8]. Synovial fluid was also obtained bilaterally at both
the 10 week and at long-term follow-up visits using aseptic
technique and needle aspiration under sedation. Joint tissue
specimens were then transported to a laboratory that was not used
for routine bacteriological research. Specimens of synovium were
divided in a laminar flow hood and portions of each biopsy were
used for estimation of bacterial load and for histology. Synovial
fluid cells were isolated by centrifugation. Synovial membrane,
synovial fluid cells, and PBMC were stored at 280C until
analyzed.
Determination of bacterial load by 16S rRNA real-time
PCR in HA/doxycycline-treated dogs
DNA was isolated from synovium and synovial fluid and
bacterial load was estimated in each sample using two broad-
ranging standard primer sets optimized for detection of comple-
mentary genera of bacteria [24,31–33]. PCR reactions were
carried out in a final volume of 25 ml using the TaqMan PCR core
reagent kit (Applied Biosystems, Foster City, CA). The master
mixture was filtered using a Centriprep YM-100 filter (Millipore,
Billerica, MA), and then 1 ml of total DNA was added. All PCR
reactions were performed in triplicate. To estimate bacterial copy
number, the threshold cycle (Ct) of each sample was analyzed
against a standard curve with serial 10-fold dilution of DNA from
10 ng to 10 fg, using DNA derived from a rapidly growing aerobic
organism previously identified in canine joints (Stenotrophomonas
maltophilia ATCC #13637, Manassas, VA) [24]. To prevent
contamination, all work was performed within a laminar flow
cabinet treated with UV light. PCR amplification was performed
in a different room from DNA extraction. Aliquots from known
negative samples were used as an extraction control in each PCR
run, in addition to negative and positive controls. PCR runs were
limited to no more than eight samples in order to minimize the risk
of handling errors during the assay.
Quantitative reverse-transcriptase-polymerase chain
reaction (qRT-PCR) of joint tissues from HA/doxycycline-
treated dogs
cDNA was generated from 0.2–1 mg of total RNA isolated from
synoviumandsynovialfluidaspreviouslydescribed[24].qRT-PCR
was performed using standard methods and SYBR green
methodology using a Bio-Rad thermocycler (MyiQ and IQ-SYBR
Green Supermix, Bio-Rad, Hercules, CA). Oligonucleotide primers
for the following genes: variable region of the beta chain of the T
lymphocyte antigen receptor (TCR Vb), CD3e, TRAP, interleukin-
17 (IL-17), IL-10, IL-4, interferon-c (IFN-c), and tumor necrosis
factor-a (TNF-a) (Table 1). The TCR complex consists of either a
TCR a/b or c/d heterodimer co-expressed at the cell surface with
invariant subunits (c, d, e, g, f) of CD3 [34,35]. Primers were
designed from known canine gene sequences or regions of
homology between the specific genes of other higher mammals.
The 18S rRNA gene was used as the housekeeping gene. All PCR
reactions were carried out as described [24]. Assays were validated
by the use of a no template control. In addition, we tested the CD3e
and TCR Vb primers using an immortalized Madin Darby canine
kidney cell line and found no expression, as would be expected with
genes that are only expressed in T lymphocytes.
Synovial membrane histology in HA/doxycycline-treated
dogs
After collection, a portion of each synovial membrane specimen
was fixed in Zamboni’s fixative for 1–2 days at 4uC [36]. Frozen
sections 10 mm thick were prepared [24] and stained with
hematoxylin and eosin. Sections were also stained histochemically
for TRAP using naphthol AS-BI phosphate as a marker for
activated macrophages [17]. For each batch of slides, a negative
control was prepared by omission of the naphthol AS-BI phosphate.
Synovial tissue sections were scored subjectively for severity of
synovial inflammation (J.A.B.) and numbers of TRAP
+ synovial
macrophages (P.M.) using a visual analog scale method [24].
Statistical Analysis
Gehan’s generalized Wilcoxon test and the Kaplan-Meier
Product-Limit estimate were used for multivariate survival analysis
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contralateral ligament survival between groups of dogs (Groups
1–3), as a baseline control. Similarly, effects of gender or breed on
contralateral ligament survival were also examined. The ten most
common breeds in the study were analyzed (in order of prevalence
in the cohort, Labrador retriever, Golden retriever, Rottweiler,
German shepherd, Cocker spaniel, Boxer, Pitbull terrier, Beagle,
Newfoundland, Mastiff). Cox’s proportional hazard model was
also used to determine whether age, gender, bodyweight, or pre-
operative TPA had significant effects on contralateral CrCL
survival. Time-dependent analysis was performed for dog age.
Gehan’s generalized Wilcoxon test and the Chi-square test were
also used to determine whether contralateral CrCL survival was
influenced by treatment with our provisional disease-modifying
therapy.
For analysis of long-term clinical follow-up data, the Kolmol-
gorov-Smironv test was used to determine whether data
approximated a normal distribution. If a dog developed
contralateral CrCLR during the study period, then this stifle was
excluded from the short- or long-term follow-up data sets.
Bacterial copy number was normalized to the DNA concentration
and the result was expressed as #/mg of DNA. For analysis of gene
expression data, the threshold cycle (Ct values) obtained from the
exponential region of the PCR amplification plot from duplicate
trials were averaged together. Relative expression for each of the
genes-of-interest was then calculated using standard curves [37].
PBMC gene expression was used as an internal control and the
18S rRNA gene was used as the housekeeping gene. Dependent
data from index and contralateral limbs were analyzed using the
Student’s t test for paired data, or the Friedman ANOVA and
Wilcoxon matched-pairs tests, as appropriate. Within each group
and time point, the single sample Student’s t test with a
hypothesized mean of zero was used to determine whether
expression of TCR Vb, CD3e, TRAP, IL-17, IL-4, IL-10, IFN-c
and TNF-a in synovial tissues and PBMC was different, after log-
transformation of data. Results were considered significant at
p,0.05.
Correlations between the development of subsequent contra-
lateral CrCLR and a priori clinical, radiographic, arthroscopic,
and synovial tissue laboratory analyses were examined using the
Pearson and Spearman Rank correlation tests. Where relevant, a
Bonferroni correction for comparisons across three time points,
such that values of p,0.025 were considered significant.
Results
Contralateral Ligament Survival
In Group 1, median survival time for the contralateral ligament
was 809 days. Subsequent contralateral rupture occurred in 67 of
125 dogs (54%). In Group 2, median survival time was 1227 days.
Subsequent contralateral rupture occurred in 45 of 84 dogs (54%).
In Group 3, median survival time was 836 days. Subsequent
contralateral rupture occurred in 92 of 171 dogs (54%) (Fig. 1).
There were no significant differences between groups in the
clinical survival of the contralateral CrCL (p=0.57). Overall,
median survival time for the contralateral ligament was 947 days
or 2.59 years; 204 of 380 dogs (54%) developed subsequent
contralateral rupture within the study period.
In the combined cohort of 380 baseline dogs, dog age (p,0.05),
TPA (p,0.05), and gender (p,0.05) all significantly influenced
contralateral CrCL survival. The effect of body weight (p=0.58)
and breed (p=0.62) were not significant. Increasing age was
associated with increased contralateral CrCL survival, whereas
increasing TPA was associated with decreased contralateral CrCL
survival (Fig. 2). Median survival time of the CrCL was longer in
male (950 days) and female (923 days) dogs, and shorter in both
castrated males (708 days) and ovariohysterectomized females (845
days).
Table 1. Canine oligonucleotide primers for quantitative real-time reverse-transcriptase polymerase chain reaction.
mRNA Targets Primer Type Olignonucleotides (59 to 39) Amplicon Size (bp) Sequence Reference
TCR-Vb Forward ACAGTGACCCTGAGATGTTCCCTT 139 Laboratory of Dr. Muir
Reverse ATCTTGCCGGGATGTCTCCTTTGT Dreitz et al. 1999 [65]
CD3a ˚ Forward CCAATTCCTTCCTACCCTTCAGAGGTAT 112 Laboratory of Dr. Muir
Reverse GAGCTGGAAAAACGGAAAGGT Nash et al. 1991 [66]
TRAP Forward TGCTGGCCACGTACAAGGT 70 Laboratory of Dr. Muir
Reverse TCATCCTGAAGGTACTGCAGGTT Partial canine sequence
IL-17 Forward CACTCCTTCCGGCTAGAGAA 71 Maccoux et al. 2007 [54]
Reverse CACATGGCGAACAATAGGG
IL-10 Forward CGCTGTCACCGATTTCTTCC 78 Wang et al. 2007 [67]
Reverse CTGGAGCTTACTAAATGCGCTCT
IL-4 Forward CATCCTCACAGCGAGAAACG 83 Wang et al. 2007 [67]
Reverse CCTTATCGCTTGTGTTCTTTGGA
IFN-c Forward GCGCAAGGCGATAAATGAAC 82 Wang et al. 2007 [67]
Reverse CTGACTCCTTTTCCGCTTCCT
TNF-a Forward GAGCCGACGTGCCAATG 79 Wang et al. 2007 [67]
Reverse CAACCCATCTGACGGCACTA
18S rRNA Forward CGCCGCTAGAGGTGAAATTCT 100 Laboratory of Dr. Svaren
Reverse CGAACCTCCGACTTTCGTTCT U. Wisconsin-Madison
Note: TCR-Vb – variable region of the beta chain of the T lymphocyte antigen receptor; TRAP – tartrate-resistant acid phosphatase; IL – interleukin; IFN – interferon; TNF
– tumor necrosis factor.
doi:10.1371/journal.pone.0025331.t001
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Of the cohort of 16 dogs, all dogs were re-examined at 10 weeks
after surgery. Thirteen dogs were re-examined at long-term follow-
up at least one year after surgery. Telephone follow-up with the
owner was obtained for the remaining 3 dogs. The 16 client-
owned dogs with stifle arthritis and CrCLR consisted of the
following breeds: Golden retriever (n=4), Labrador retriever
(n=3), and individual dogs of other breeds: American bulldog,
Blood hound, Chesapeake Bay retriever, German shorthair
pointer, Great Dane, Mastiff, Samoyed, Siberian Husky, Saint
Bernard. In this group of dogs, age was 5.262.5 years and body
weight was 40.767.2 kg. Eight dogs were ovariohysterectomized
females, 7 dogs were castrated males, and 1 dog was an intact
male. Median duration of lameness was 19.5 weeks (range 1–156
weeks). None of the dogs had concurrent systemic disease, and all
contralateral stifles were determined to be clinically stable by
palpation under general anesthesia at diagnosis. At surgery,
tearing of the medial meniscus was identified in the index stifle of 7
of 16 dogs (44%). No meniscal tears were found in the
contralateral stable stifle.
All dogs were re-examined to evaluate clinical function and
tibial osteotomy healing (10.261.3 weeks after surgery). By this
Figure 1. Contralateral cranial cruciate ligament (CrCL) survival. Kaplan-Meier plot for contralateral CrCL survival in three large populations
of client-owned dogs. Overall median survival was 2.59 years. There was no significant difference in ligament survival between groups (p=0.57).
Complete – dogs that experienced contralateral CrCLR during the study period; Censored – dogs that did not experience contralateral CrCLR during
the study period.
doi:10.1371/journal.pone.0025331.g001
Figure 2. Tibial plateau angle (TPA) and age influence contralateral cranial cruciate ligament (CrCL) survival over time in dogs
diagnosed with unilateral CrCL rupture. (A) Increasing TPA was associated with decreased contralateral CrCL survival, whereas increasing age at
diagnosis was associated with increased contralateral CrCL survival (B). However, these effects appear minor, as the slope of the regression lines is
small and data points are widely scattered.
doi:10.1371/journal.pone.0025331.g002
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62 days after surgery. In the remaining 15 dogs, the contralateral
stifle remained clinically stable. At long-term follow-up, an
additional 4 dogs developed subsequent contralateral CrCLR,
yielding a one-year incidence of 5 of 16 dogs (31%), which was not
significantly different from the Group 3 dogs (p=0.12). In two
dogs with subsequent contralateral CrCLR, fraying of the CrCL
was previously identified arthroscopically and estimated to involve
10% of the ligament, another dog was estimated to have a tear
involving 30% of the ligament; in the two remaining dogs with
subsequent contralateral CrCLR only minimal superficial fraying
was observed.
One dog died during the study period shortly before the one-
year long-term follow-up recheck examination was due. Doxycy-
cline and intra-articular hyaluronic acid treatment after arthro-
scopic joint examination did not significantly influence contralat-
eral CrCL survival time to rupture, when compared to the control
population of 380 dogs that did not receive the provisional disease-
modifying therapy (p=0.87, Fig. 3).
Clinical metrology data were obtained from 11 of 13 dogs that
were re-examined. Overall, load score showed a significant
improvement in mobility at one-year after surgery, when
compared with mobility at the time of initial diagnosis (p,0.05).
LOAD scores were 21611 and 1067 immediately before surgery
and at long-term follow-up respectively.
Force-plate analysis-of-gait was performed in 10 of 15 dogs at
long-term follow-up. In 8 dogs, the contralateral stifle was
determined to be clinically stable at recheck, whereas in the
remaining two dogs, contralateral CrCLR was diagnosed. In the
dogs with stable contralateral stifles at recheck, no significance
differences in Fz or VI were found between index and contralateral
stifles during force-plate analysis-of-gait (p.0.05, Table 2); Fz was
higher in the stable contralateral pelvic limb, with an index-
contralateral difference in Fz of 24.6%. At follow-up, both of the
dogs that developed subsequent contralateral CrCLR and under-
went gait analysis exhibited reduced weight-bearing in the
contralateral stifle (index-contralateral difference in Fz was 43.7%).
Stifle radiography in HA/doxycycline-treated dogs
Radiographic scores for overall change were significantly worse
in the unstable index stifle, when compared to the stable
contralateral stifle (p,0.05, Table 3). In the stable contralateral
stifle, effusion was identified in 12 of 16 stifles (75%) and all index
stifles, and arthritis was identified in 15 of 16 stifles (94%), and all
index stifles. Although the scores for overall change became higher
over time, these changes were not significant in both the index and
stable contralateral stifle (p.0.12 and p.0.11 respectively).
Synovial effusion was also significantly worse in the index stifle
at diagnosis, when compared with the stable contralateral stifle
(p,0.01), although this difference was not significant at the
recheck visits. Scores for synovial effusion did not change
significantly over time in both the index and stable contralateral
stifle (p.0.78 and p.0.14 respectively).
Stress radiographic measurements supported the finding of
clinical stability in the contralateral stifles at initial diagnosis. In the
contralateral stifles that remained clinically stable over time, there
were no significant differences in tibial translation ratio [median
(range) at diagnosis of 0.025 (0.000–0.106), n=11; 1 year follow-
up ratio was 0.025 (0.00–0.048), n=7]. However, in the 3 dogs
that were determined to have experienced subsequent contralat-
eral CrCLR at long-term follow-up visit, cranial tibial translation
ratio was higher [0.075 (0.073–0.184)].
Figure 3. Contralateral cranial cruciate ligament (CrCL) survival after post-operative treatment with provisional disease-modifying
therapy. Kaplan-Meier plot for contralateral CrCL survival in a population of client-owned dogs treatment with oral doxycycline after TPLO
stabilization of unilateral CrCLR. Arthroscopic examination and associated lavage of the contralateral stable stifle, together with intra-articular
hyaluronic acid and oral doxycycline did not significantly influence CrCL survival (p=0.87). Complete – dogs that experienced contralateral CrCLR
during the study period; Censored – dogs that did not experience contralateral CrCLR during the study period.
doi:10.1371/journal.pone.0025331.g003
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treated dogs
Both unstable index and stable contralateral stifles had
macroscopic and histologic evidence of synovitis. Synovitis
assessed arthroscopically was significantly increased in the index
stifle, when compared with the contralateral stable stifle (p,0.001,
Table 4). Histologic synovitis was present in both stifles, with
elevated severity scores in the unstable stifle; sub-intimal
mononuclear inflammatory cells were often found (Fig. 4).
Numbers of TRAP
+ mononuclear cells were increased in the
unstable index stifle, when compared with the contralateral stable
stifle. TRAP
+ mononuclear cells were identified in 11 of 14
unstable stifles, but only 2 of 10 stable stifles (Fig. 4).
No significant changes in bacterial load were identified using the
Nadkarni 16S rRNA universal primer set. With the Yang 16S
rRNA universal primer set, bacterial load within synovial fluid was
increased in the contralateral stifle versus the unstable index stifle
at diagnosis (p,0.05, Table 5). At the 10-week recheck, bacterial
load in synovial fluid in the unstable stifle was increased when
compared to diagnosis (p,0.01, Table 5). Bacterial load in
synovial fluid in the contralateral stable stifle was also higher at the
10-week recheck (p=0.11).
Synovial tissue gene expression in HA/doxycycline-
treated dogs
Results are summarized in Table 6. Overall, expression of
TCR Vb and CD3e were highly correlated (SR=0.79, p,0.0001).
At diagnosis, expression of TCR Vb, CD3e, IL-10, IFN-c, and
TRAP in synovium was increased in the unstable index stifle,
when compared with the stable contralateral stifle (p,0.05).
Expression of TNF-a was increased in synovial fluid in the
unstable index stifle, when compared with the stable contralateral
stifle (p,0.01).
At the 10-week recheck, expression of IFN-c (p,0.05), TRAP
(p,0.01), and TNF-a (p,0.05) in synovial fluid in the unstable
index stifle was also higher, when compared with the stable
contralateral stifle. Expression of IL-10 (p,0.01) in synovial fluid
from the unstable index stifle was also increased, when compared
to diagnosis. No significant differences in gene expression were
detected at the one-year recheck.
Correlative analyses in HA/doxycycline-treated dogs
Arthroscopic VAS synovitis severity score (r
2=0.57, p=0.005)
and the presence of TRAP
+ mononuclear cells in the stable stifle
synovium (SR=0.63, p=0.05) were significantly related to
histologic synovitis score at diagnosis. No significant correlation
was detected in the unstable index stifle. At diagnosis, bacterial
load in synovium and synovial fluid was not significantly related to
arthroscopic or histologic severity score, or numbers of TRAP
+
mononuclear cells in either stifle. Bacterial load was not
significantly correlated with histologic inflammation or synovial
gene expression at diagnosis, except that bacterial copy number
estimated using the Nadkarni primers was correlated with
expression of TNF-a in synovial fluid in the stable contralateral
stifle (SR=0.6, p,0.05). In the unstable stifle at diagnosis,
histologic synovitis was inversely correlated with expression of
IL-4 in synovium (SR=20.77, p=0.001). Additionally, the
presence of TRAP
+ mononuclear cells in synovium was signifi-
cantly correlated with IL-10 expression in synovium (SR=0.69,
p,0.01). No significant correlations between the presence of a tear
in the medial meniscus of the unstable index stifle and any marker
of stifle joint inflammation were found.
Correlative analysis between a priori clinical variables and
development of subsequent contralateral rupture revealed few
significant results. Radiographic assessment of stifle arthritis and
effusion, and arthroscopic assessment of synovial inflammation
and CrCL fiber tearing were not significantly correlated with
subsequent contralateral CrCLR. Pre-operative TPA was not
significantly correlated with development of subsequent contralat-
eral CrCLR.
At diagnosis, histologic inflammation in the unstable (SR=0.39,
p=0.17) and stable stifle (SR=0.47, p=0.13) was not significantly
related to subsequent contralateral rupture. Expression of CD3e in
synovium in the unstable stifle was significantly related to
subsequent contralateral CrCLR (SR=0.60, p=0.01), although
this was not significant for the stable contralateral stifle. There was
also a similar trend for expression of TCR Vb and TRAP in
unstable stifle synovium (SR=0.54, p=0.03 and SR=0.52,
p=0.05 respectively). Expression of IL-17 in synovial fluid in the
stable stifle was inversely correlated with development of
Table 2. Force-plate analysis-of-gait at long-term follow-up after surgical stabilization and hyaluronic acid/doxycycline treatment
of stifle arthritis in dogs with unilateral cranial cruciate ligament rupture.
Parameter Index stifle Contralateral Stifle Index-Contralateral difference (%) Significance
Peak Vertical Force 46.468.9 48.5611.9 24.6 NS
Vertical Impulse 14.163.9 13.662.9 3.5 NS
Note: Data represent mean 6 standard deviation. n=8 dogs; NS – not significant (p.0.05).
doi:10.1371/journal.pone.0025331.t002
Table 3. Radiographic signs of stifle arthritis and synovial
effusion in dogs with unilateral cranial cruciate ligament
rupture after surgical stabilization and hyaluronic acid/
doxycycline treatment.
Composite Score [28] Index stifle Contralateral Stifle Significance
Diagnosis 6.5 (4–10) 4.5 (0–8) p,0.005
10 weeks after surgery 7 (4–8) 4 (2–7) p,0.005
1 year after surgery 8 (6–8) 6 (5–7) p,0.05
Synovial Effusion [28]
Diagnosis 2 (1–2) 1 (0–2) p,0.01
10 weeks after surgery 2 (1–2) 2 (0–2) NS
1 year after surgery 2 (1–2) 2 (1–2) NS
Data represent median (range). Diagnosis, n=16; 12 weeks after surgery, n=15;
1 year after surgery, n=8. NS – not significant (p.0.05). Changes in composite
score and synovial effusion were not significantly different over time. One dog
was excluded from the analysis at the 10 week recheck, because of
development of contralateral CCLR at 67 days after surgery, 5 dogs were
excluded at long-term follow-up.
doi:10.1371/journal.pone.0025331.t003
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tions with IL-10, IL-4, IFN-c, and TNF-a were not significant.
Discussion
It has been recognized for some time that dogs affected with
CrCLR often ultimately develop bilateral ruptures. Bilateral
rupture may be diagnosed at initial presentation, or by
development of subsequent contralateral CrCLR, often within a
relatively short period of time from diagnosis. Risk of subsequent
contralateral CrCLR has typically been reported as a proportion
at long-term follow-up, often around one year from diagnosis
[2,3,5–7]. This risk is in the range of 22–54% [2,3,5–7]. In the
present study, this risk was 54% and was remarkably similar in the
different cohorts within the study. Median survival time to
subsequent contralateral CrCLR in our large baseline population
of dogs treated surgically for unilateral rupture was 947 days
overall. Interestingly, the Kaplan-Meier survival plot yielded an
exponential shaped curve, particularly for Groups 1 and 2, which
had the longest follow-up periods. The shape of the survival curve
suggests that within the overall population, there are individual
dogs that are protected from the trait, with a long contralateral
CrCL survival time, as well as individual dogs that are susceptible
to the trait and more rapidly experience subsequent contralateral
Figure 4. Photomicrographs of stifle synovium from dogs with unilateral cranial cruciate ligament rupture and a contralateral
stable stifle. (A) Unstable stifle of a five-year-old neutered male Golden Retriever. Proliferation of the synovial intima with villus formation can be
seen. Widening of intima (arrows) and infiltration of the intima and sub-intima with mononuclear inflammatory cells can also be seen. (B) Unstable
stifle of a five-year-old Chesapeake Bay Retriever. TRAP
+ mononuclear cells (arrows) were identified in synovial villi in the intima and sub-intimal
tissues. (C) Stable stifle from a six-year-old neutered male Golden Retriever. Proliferation of the synovial intima can also be seen, with accumulation of
mononuclear inflammatory cells within the intima and the sub-intimal tissues (arrows). A,C – Hematoxylin and eosin stain; B – histochemical stain for
tartrate-resistant acid phosphatase (TRAP). A – bar=500 mm; B – bar=200 mm; C – bar=100 mm.
doi:10.1371/journal.pone.0025331.g004
Table 4. Synovial inflammation in the unstable index and stable contralateral stifles of dogs with unilateral cranial cruciate
ligament rupture.
Unstable Index Stifle Stable Contralateral Stifle Significance
NRS Arthroscopic Synovitis (n=16) 19 (11, 22) 12 (4, 20) p,0.001
VAS Arthroscopic Synovitis (n=16) 63621 35620 p,0.001
Histologic inflammation (n=12–14) 33623 20620 NS
TRAP
+ mononuclear cells (n=10–14) 19 (0, 42) 0 (0, 31) p,0.05
Note: Synovitis was scored subjectively using arthroscopy using a compartmental numerical rating scale (NRS, score range 0–24) and a visual analogue scale (VAS).
Histologic sections of synovium were also subjectively graded for inflammation and numbers of TRAP
+ mononuclear cells using a visual analogue scale; severity scores
ranged from 0 (no inflammation) to 100 (could not be more severely inflamed). NS – not significant.
doi:10.1371/journal.pone.0025331.t004
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fully understood. However, the presence of stifle synovitis
histologically increases the risk of subsequent contralateral CrCLR
[10], although there is no evidence of a MHC class II
immunogenetic association [38]. Non-contact CrCLR is a
complex trait, with multiple genes contributing to development
of the phenotype [39]. Heritability is estimated to be 0.27 in
Newfoundlands, suggesting that extrinsic factors also have a
substantial effect on expression of the phenotype [40].
Both intrinsic and extrinsic factors are thought to contribute to
the risk of developing CrCLR. Intrinsic factors include genetics,
cruciate ligament matrix composition, stifle morphology, and body
weight. Extrinsic factors include body condition, whether or not
ovariohysterectomy or castration has been performed, and
development of synovitis [4,10,39–45]. In the present study, we
examined the effect of gender, breed, body weight, age, and TPA
on risk of subsequent contralateral CrCLR in a large population of
dogs. The effects of breed and body weight were not significant.
However, we found that TPA significantly influenced the risk of
contralateral CrCLR, suggesting that stifle morphology and
functional loading of the CrCL during daily life is a risk factor
for CrCLR, although this was not confirmed in our smaller cohort
of dogs treated with HA/doxycycline. Although stifle morpholog-
ical factors appear to confer some risk of CrCLR, stifle
Table 5. Bacterial load in the unstable index and stable contralateral stifles of dogs with unilateral cranial cruciate ligament
rupture.
16S rRNA Universal Primer Set Unstable Index Stifle Stable Contralateral Stifle
Diagnosis 10 Week Recheck Diagnosis 10 Week Recheck
Synovium Synovial fluid Synovial fluid Synovium Synovial fluid Synovial fluid
Yang et al., (2002) [32] 53 (8, 1124) 41 (1, 514) 459
## (7, 7931) 93 (10, 392) 212
* (1, 2474) 1021 (86, 3882)
Nadkarni et al., (2002) [31] 40 (5, 442) 13 (3, 98) 15 (2, 64) 45 (2, 589) 17 (3, 89) 15 (2, 46)
Note: Data represent median (range). Bacterial load represents estimated 16S rRNA amplicon number using universal primers and real-time PCR.
*p,0.05 versus contralateral joint.
##p#0.01 versus same tissue at diagnosis. (n=13 to 16 dogs per group).
doi:10.1371/journal.pone.0025331.t005
Table 6. Relative expression of immune response genes in synovial fluid from unstable index and stable contralateral stifles of
dogs with unilateral cranial cruciate ligament rupture.
Synovium Synovial fluid
Gene Unstable Index Stifle
Diagnosis 10 Week Recheck 1 Year Recheck
TCR Vb
**0.03 (0.00, 3.33) 0.61 (0.01, 9.89) 0.64 (0.06, 13.8) 0.21 (0.05, 8.49)
CD3e
*0.02 (0.00, 2.47) 0.69 (0.01, 3.08) 0.20 (0.03, 2.24) 0.1 (0.01, 1.24)
IL-17 2.59 (0.16, 337) 3.84 (0.04, 451) 1.76 (0.08, 232)
IL-10
** 7.98 (0.21, 184) 14.2 (0.00, 331)
##55.0 (0.13, 1686)
IL-4 1.10 (0.00, 35.4) 4.64 (0.27, 112) 1.17 (0.01, 785)
IFN-c
**1.38 (0.01, 10480) 12.4 (0.01, 3572)
*8.99 (0.51, 100)
TRAP
**1.08 (0.01, 95.9) 5.78 (0.48, 53.9)
**24.4 (0.06, 124)
TNF-a 0.11 (0.00, 5.39)
**2.06 (0.00, 18.6)
*1.39 (0.32, 14.9) 2.75 (0.20, 16.8)
Stable Contralateral Stifle
TCR Vb 0.02 (0.00, 0.18) 0.11 (0.01, 43.03) 0.21 (0.00, 1711) 0.40 (0.07, 1.16)
CD3e 0.02 (0.00, 0.08) 0.15 (0.01, 22.3) 0.04 (0.00, 1270) 0.17 (0.05, 1.00)
IL-17 2.71 (0.00, 122) 4.58 (0.05, 23347) 1.87 (0.00, 84)
IL-10 1.00 (0.02, 18.0) 17.0 (0.04, 98.3) 29.0 (0.18, 250)
IL-4 0.80 (0.01, 15.8) 2.11 (0.00, 153) 17.1 (0.80, 139407)
IFN-c 0.33 (0.00, 761) 0.63 (0.02, 126) 0.73 (0.00, 137)
TRAP 0.11 (0.01, 2.92) 2.28 (0.26, 36.6) 1.87 (0.03, 92.0)
TNF-a 0.04 (0.00, 0.42) 0.31 (0.00, 9.41) 0.38 (0.00, 5.50) 1.10 (0.46, 6.39)
Note:T C RV b - beta chain of the canine T cell receptor; TRAP – tartrate-resistant acid phosphatase; IL – interleukin; IFN – interferon; TNF – tumor necrosis factor.D a t a
represent median (range). Median values in bold indicate that gene expression is significantly different from the peripheral blood mononuclear cell internal control
(p,0.05).
*p,0.05,
**p,0.01 versus contralateral stifle.
##p,0.01 versus same tissue at diagnosis. n=15–16 at diagnosis, n=14–15 at 10 week recheck, n=5–7 at 1 year recheck.
doi:10.1371/journal.pone.0025331.t006
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primary causative factor [46]. The age range when CrCLR
develops is typically between 2–10 years [43,44]. In the present
study, we found that age significantly influenced CrCL survival,
with increasing age being associated with increased contralateral
CrCL survival, although this effect also appeared small in
magnitude. This observation also fits with the concept that our
overall study population consisted of dogs with a mixture of
intrinsic (genetic) susceptibility to the CrCLR trait. Neutered dogs
also had shortened contralateral CrCL survival, as previously
described [43,44].
In a second experiment, we examined long-term CrCL survival
in a small cohort of dogs with unilateral CrCLR that were treated
with HA/doxycycline and surgical stabilization of the index stifle.
We did not find a significant treatment effect with our provisional
disease-modifying therapy. Correlative analysis revealed few
significant associations between markers of stifle disease and
subsequent development of contralateral CrCLR, although
increased expression of T-cell associated genes in the unstable
stifle at diagnosis was correlated with development of subsequent
contralateral CrCLR. This observation fits with the concept that
the presence of stifle synovitis is related to the risk of subsequent
contralateral CrCLR [10], although the correlation between
expression of IL-17 in synovial fluid in the stable stifle and
development of subsequent contralateral CrCLR that we detected
was an inverse one. Further work is needed studying association of
the trait with MHC genotype, although current evidence suggests
a strong class II association is unlikely [38]. Bacterial load was not
significantly correlated with histologic synovitis, although in-
creased copy number was detected in the unstable stifle, which
increased over time. Although we have previously reported
association and weak correlation between bacterial load and stifle
synovitis/arthritis in CrCLR dogs [22–24], collectively these
results suggest that bacterial load is not a key factor in
development of stifle synovitis in affected dogs.
In this proof-of-principle study, we selected the test compounds
used in the trial based on existing literature in the field of disease-
modifying therapy, including both anti-inflammatory compounds,
as well as compounds that may ameliorate connective tissue matrix
degradation over time. Additionally, both of the treatments used
are generic and inexpensive. Doxycycline has been widely studied
as a potential therapeutic drug for arthritis. In-vitro, doxycycline
can inhibit gelatinase-mediated degradation of type XI collagen,
reduce activation of collagenase, and inhibit mRNA for inducible
nitric oxide, a mediator of tissue catabolism [26,47,48]. In-vivo
studies in dogs suggest that treatment can modify development of
arthritis over time [27], using a treatment regimen of similar
duration and dosage to that of the present study. Indirectly, this
may suggest that disease-modifying therapy that targets synovial
inflammation may be a more effective treatment strategy than
therapy that targets ligament matrix degeneration, as the
doxycycline regimen used in this study did not significantly
influence CrCL survival. An additional point supporting this
concept is the recent observation that synovitis is an early event in
canine non-contact CrCL rupture, which precedes development of
arthroscopically visible fraying of the cruciate ligament complex
[8].
HA has also been widely studied as a disease-modifying
treatment for arthritis both as a course of intra-articular injections,
as well as using a single injection protocol [49,50]. Potential
therapeutic effects on arthritic joints from intra-articular HA
injection are complex and include reduction in both synovial
inflammation, and connective tissue matrix degeneration through
inhibition of MMP-13 expression, for example [51]. Pro-
inflammatory effects of HA fragmentation may occur through
CD44 signaling [52]. However, treatment with intra-articular HA
did not reduce CD44 expression in OA joints experimentally in an
ovine meniscectomy model, but did reduce synovial vascularity
and subintimal fibrosis [49]. In the present study, we also used
arthroscopy to examine both the index and contralateral stifles at
initial diagnosis [8]. The joint lavage associated with the
arthroscopic procedure has the potential to exert a disease-
modifying effect, by reducing synovial inflammation and produc-
tion of pro-inflammatory cytokines, such as TNF-a [53].
In the dogs in this cohort, overall mobility was significantly
improved at long-term follow-up, with equalization of weight-
bearing between the index stifle treated with TPLO and the
contralateral stifle, except for the dogs that developed subsequent
contralateral CrCLR during the study period. Radiographic signs
of arthritis were significantly worse in the unstable index stifle.
There was also some evidence of worsening synovial effusion in the
stable contralateral stifle over time, although no clinical or
radiographically detectable changes in stability were identified.
Synovial effusion was significantly worse in the index stifle at
diagnosis, but not at the follow-up visits. Similarly, there was little
change in expression of gene markers for T cells and macrophages
over time. Increases in expression of the T-cell associated genes
TCR Vb, CD3e, and IFN-c that were identified in the unstable
index stifle relative to the contralateral stable stifle were principally
identified at diagnosis, although expression of IFN-c remained
increased in the unstable stifle at the 10 week recheck. Up-
regulation of macrophage-associated genes (IL-10, TRAP, and
TNF-a) was also identified in the unstable stifle at diagnosis and
also at the 10-week recheck; there was no significant difference in
TNF-a between index and contralateral stifles at the one-year
recheck. These observations suggest that development of stifle
synovitis may be mediated via T lymphocyte and macrophage
signaling, which was not influenced by oral doxycycline treatment.
Interestingly, IL-10 was the only gene whose expression was
increased in synovial fluid from the unstable stifle at the 10-week
recheck. Relative expression was also higher in the contralateral
stable stifle. IL-10 is a cytokine with anti-inflammatory properties
that is typically up-regulated in arthritic joints [54,55]. Up-
regulation of IL-10 in both stifles relative to internal control, with
increased expression over time suggests that immune regulating
cells, such as macrophages and regulatory T cells, are acting to
inhibit effector T cells and activated macrophages, and suppress
synovial inflammation in affected joints. In humans with
rheumatoid arthritis, there is impairment of regulatory T cell
function [56]. Polymorphisms in the promotor region of IL-10 are
known to influence the risk of rheumatoid arthritis in human
beings, by reducing IL-10 transcription and decreasing circulating
IL-10 [57]. Similarly, IL-10 polymorphisms have been associated
with immune-mediated disease in the dog [58]. Whether there is
functional impairment of anti-inflammatory cytokine responses in
dogs with stifle synovitis and non-contact CrCL rupture has not
been determined. In the present study, the presence of TRAP
+
mononuclear cells in synovium was significantly correlated with
IL-10 expression in the unstable stifle at diagnosis, supporting the
concept that IL-10 production by activated macrophages may be a
functionally important anti-inflammatory factor within the joint
environment, acting to ameliorate synovitis in this disease.
Although we did not identify an obvious treatment effect on
CrCL survival, or significant progression of arthritis pathology
over time, the lack of a treatment effect from arthroscopic lavage
and associated medical therapy suggests that this in-vivo client-
owned canine model of unilateral CrCLR (with contralateral
incipient disease) may be valuable for future mechanistic and
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contact CrCLR in client-owned dogs is substantially different from
traumatic CrCLR modeled by CrCL transection in the Pond-Nuki
model [59], and has many similarities to the non-contact minimal
trauma ACL rupture that is common in human beings,
particularly women [60,61].
The lack of a significant treatment effect in this cohort, with a
31% contralateral rupture rate at one year, also suggests that our
arthroscopic findings in the stable stifle at diagnosis are a valid
reflection of incipient disease. Arthroscopic grading of synovitis
has been widely performed in human beings with arthritic
conditions [62], but not in dogs [8]. All client-owned dogs had
medical treatment with non-steroidal anti-inflammatory drugs of
variable duration before inclusion in this study [8], but this
medical therapy did not prevent development of subsequent
contralateral CrCLR in the cohort.
This study had several limitations. A potential concern with our
ligament survival analysis was that limited phenotypic and clinical
status data were available for each dog. It is common for CrCLR-
affected dogs to be treated with a non-steroidal anti-inflammatory
drug (NSAIDs). Whether NSAID medication has any effect on
CrCL survival could not be determined from the present study.
Given that stifle synovitis increases the risk of subsequent
contralateral CrCLR in client-owned dogs [10], in future work it
would be interesting to determine, in more detail, whether or not
synovitis and the presence of specific T cell subsets in joint tissues
or peripheral blood [63] have a significant effect on contralateral
CrCL survival over time. Although difficult to obtain in a client-
owned dog model, follow-up second-look arthroscopy and synovial
biopsies may have also yielded additional data on synovitis status
over time. Several dogs in the treatment cohort developed
subsequent contralateral rupture during the study period.
Collection and analysis of additional stifle joint tissue samples in
these dogs at the time of contralateral stifle stabilization surgery
may also have been informative. More detailed study of the
phenotype of the inflammatory cells within the synovium of stable
stifles [63] and analysis of other biomarkers of joint inflammation,
such as C-reactive protein [64], may also have yielded additional
data on the relationship between synovitis and development of
non-contact CrCLR. In addition, mobility questionnaire data
were obtained retrospectively at long-term follow-up. Although
efficacy of intra-articular HA has been described after use of a
single injection [50], treatment is often given as a course of
injections [49]. Efficacy of HA treatment may have been improved
with a course of intra-articular injections, although risk of adverse
effects may also be increased.
In conclusion, subsequent contralateral CrCLR is common in
client-owned dogs, with a median ligament survival time of 947
days. Treatment with arthroscopic lavage, single intra-articular
HA injection, and oral doxycycline does not significantly influence
contralateral CrCL survival. In this client-owned model of stifle
arthritis and non-contact minimal trauma CrCLR, development
of cranial tibial translation is preceded by development of synovial
inflammation, superficial fraying of the cruciate ligament complex,
and rupture of ligament fibers, particularly within the caudolateral
bundle of the CrCL [8]. The immunological mechanism that
induces development of synovitis in stable stifles with incipient
CrCLR should be the focus of future work on identification of
targets for disease-modifying therapy. Here T cell-mediated
synovitis appears important. More work is also needed on
identification of a genetic marker or a clinically relevant biomarker
that is a good predictor of progressive ligament rupture over time.
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